Soleno Therapeutics Secures $200M to Propel Illimis Therapeutics’ Breakthrough Neurodegenerative Disease Platform

Soleno Therapeutics, Inc. is thrilled to announce a landmark funding milestone, having raised $200 million in its recent financing round. This substantial investment underscores the confidence that investors have in the company’s innovative approach to tackling some of the most challenging neurodegenerative diseases, including Alzheimer’s. At the forefront of biotech innovation, Soleno Therapeutics is pioneering a chimeric fusion protein platform designed to address critical limitations in existing antibody drugs. Unlike traditional treatments that often lead to antibody-induced neuroinflammation and ARIA (Amyloid-Related Imaging Abnormalities) due to FcR-mediated phagocytosis of microglia, our platform leverages the novel TAM receptor on glial cells—a breakthrough that promises enhanced safety and efficacy. The funding will be strategically deployed to accelerate the development of this unique platform, enabling deeper research into its mechanistic advantages and paving the way for early-stage clinical trials. By focusing on refining our technology to mitigate the adverse effects seen with current therapies, Soleno Therapeutics aims to deliver a more targeted treatment option that not only reduces complications but also offers the potential for improved outcomes in patients suffering from Alzheimer’s and related neurodegenerative conditions. This robust financing round marks a significant step forward for our mission-driven company, affirming our commitment to transforming therapeutic landscapes and meeting unmet medical needs. With these new resources, Soleno Therapeutics is poised to intensify its research efforts, expand strategic collaborations, and ultimately bring innovative, safer, and more effective treatments to patients worldwide. We look forward to the next phase of our journey, guided by science, innovation, and an unwavering dedication to improving lives.